{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"condition":["Advanced Solid Tumor","Neoplasms"],"disease":["Advanced Solid Tumor","Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/108891"],"location":["China"],"study_start_month":["9"],"keyword":["KRAS mutation","Pancreatic carcinoma","Nonsmall-cell lung cancer（NSCLC）","Colorectal cancer（CRC）"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A Study of YL-17231 in Patients With Advanced Solid Tumors","description":"This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of oral YL-17231 in patients with advanced solid tumors with KRAS mutation, so as to confirm the recommended phase 2 dose of YL-17231 and obtain the preliminary efficacy information of patients with advanced solid tumors with KRAS mutation.","dates":{"creation":"2023-09-15"},"accession":"108891","cross_references":{"ClinicalTrials___gov":["NCT06078800"]}}